Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Emergent BioSolutions (NYSE: EBS), a public health company focused on protective and life-saving solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Joe C. Papa, the company's president and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 1:30 PM PST.
The presentation will be accessible through an audio link, which will remain available for 30 days following the event. Additionally, the presentation slides will be published in the Investors section of Emergent's website coinciding with the presentation time.
Emergent BioSolutions (NYSE: EBS), un'azienda di sanità pubblica focalizzata su soluzioni protettive e salvavita, ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference. Joe C. Papa, presidente e CEO dell'azienda, terrà una presentazione mercoledì 15 gennaio 2025, alle 13:30 PST.
La presentazione sarà accessibile tramite un link audio, che rimarrà disponibile per 30 giorni dopo l'evento. Inoltre, le diapositive della presentazione saranno pubblicate nella sezione Investitori del sito web di Emergent in coincidenza con l'orario della presentazione.
Emergent BioSolutions (NYSE: EBS), una empresa de salud pública enfocada en soluciones protectoras y salvavidas, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan. Joe C. Papa, presidente y CEO de la empresa, realizará una presentación el miércoles 15 de enero de 2025, a la 1:30 PM PST.
La presentación estará disponible a través de un enlace de audio, que permanecerá accesible durante 30 días después del evento. Además, las diapositivas de la presentación se publicarán en la sección de Inversores del sitio web de Emergent coincidiendo con el horario de la presentación.
Emergent BioSolutions (NYSE: EBS), 보호 및 생명 구호 솔루션에 중점을 둔 공공 보건 기업, 제43회 연례 J.P. Morgan 헬스케어 컨퍼런스에 참가한다고 발표했습니다. Joe C. Papa 회사의 사장이자 CEO가 2025년 1월 15일 수요일 오후 1:30 PST에 발표를 진행할 예정입니다.
발표는 오디오 링크를 통해 접근 가능하며, 이벤트 이후 30일 동안 이용할 수 있습니다. 또한 발표 슬라이드는 발표 시간에 맞춰 Emergent 웹사이트의 투자자 섹션에 게시될 예정입니다.
Emergent BioSolutions (NYSE: EBS), une entreprise de santé publique axée sur des solutions protectrices et salvatrices, a annoncé sa participation à la 43e Conférence annuelle J.P. Morgan sur les soins de santé. Joe C. Papa, le président et CEO de l'entreprise, effectuera une présentation le mercredi 15 janvier 2025, à 13h30 PST.
La présentation sera accessible via un lien audio, qui restera disponible pendant 30 jours après l'événement. De plus, les diapositives de la présentation seront publiées dans la section Investisseurs du site Web d'Emergent en même temps que l'heure de la présentation.
Emergent BioSolutions (NYSE: EBS), ein Unternehmen im Bereich der öffentlichen Gesundheit, das sich auf schützende und lebensrettende Lösungen spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Joe C. Papa, der President und CEO des Unternehmens, wird am Mittwoch, den 15. Januar 2025, um 13:30 Uhr PST eine Präsentation halten.
Die Präsentation wird über einen Audio-Link zugänglich sein, der 30 Tage nach der Veranstaltung verfügbar bleibt. Darüber hinaus werden die Präsentationsfolien zur gleichen Zeit im Investorenbereich der Website von Emergent veröffentlicht.
- None.
- None.
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that Joe C. Papa, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM PST.
The audio link for Emergent's session may be accessed here and will be live for up to 30 days.
The company’s slides will be made available at the time of the presentation on the Investors section of the Emergent website.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we help protect public health, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
When is Emergent BioSolutions (EBS) presenting at the J.P. Morgan Healthcare Conference 2025?
How long will the EBS presentation audio be available for listening?
Where can investors find EBS's J.P. Morgan Healthcare Conference presentation slides?
Who will represent EBS at the 2025 J.P. Morgan Healthcare Conference?
